Displaying drugs 11001 - 11025 of 11745 in total
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety …
Lazertinib
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Investigational
Matched Description: … Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib …
Veliflapon
Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Investigational
Matched Description: … clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a …
Nadecnemab
Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).
Investigational
Matched Description: … Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory …
1D09C3
1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include...
Investigational
Matched Description: … 1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex ... B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a …
CR665
CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists. In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound. In addition, unlike currently marketed opioids, CR665 does...
Investigational
Matched Description: … Preclinical animal studies suggest that CR665 is a potent analgesic compound. ... CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid …
Melperone
Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It has been well established in the treatment of confusion, anxiety, restlessness (particularly in...
Investigational
Matched Description: … Melperone has been used for a span of greater than 30 years in the European Union [L1316]. ... Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. …
Didesmethylrocaglamide
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of …
V590
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational
Matched Description: … By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one ... Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow …
(R)-Propylene glycol
A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
Experimental
Matched Description: … A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations. …
Cadaverine
Cadaverine is a foul-smelling diamine formed by bacterial decarboxylation of lysine.
Experimental
Matched Description: … Cadaverine is a foul-smelling diamine formed by bacterial decarboxylation of lysine. …
Motuporin
Motuporin is a toxin isolated from the marine sponge Thenonella swinhoie grey.
Experimental
Matched Description: … Motuporin is a toxin isolated from the marine sponge Thenonella swinhoie grey. …
Ketodarolutamide
Ketodarolutamide, a nonsteroidal antiandrogen (NSAA), is the major active metabolite of darolutamide.
Experimental
Matched Description: … Ketodarolutamide, a nonsteroidal antiandrogen (NSAA), is the major active metabolite of [darolutamide …
IVT-8086
IVT-8086 is a humanized secreted frizzled-related protein-2 monoclonal antibody.
Investigational
Matched Description: … IVT-8086 is a humanized secreted frizzled-related protein-2 monoclonal antibody. …
GSBR-1290
GSBR-1290 is a small molecule agonist of the GLP-1 receptor.
Investigational
Matched Description: … GSBR-1290 is a small molecule agonist of the GLP-1 receptor. …
Ezatiostat
Ezatiostat is investigated in clinical trials for treating myelodysplastic syndrome. This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen...
Investigational
Matched Description: … It might also be relevant as an adjunct therapy since a reduction in blood cell levels is also a common ... Ezatiostat is a small molecule drug that is an analog inhibitor of glutathione S-transferase P1-1. ... amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a …
NPI 32101
NPI 32101 possesses both anti-inflammatory and broad spectrum antimicrobial activities. This combination of pharmacological properties may have additional therapeutic uses beyond dermatology.
Investigational
Putrescine
Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. Putrescine is a solid. This compound belongs to the polyamines. These are compounds containing more than one amine group. Known drug targets of putrescine include putrescine-binding periplasmic protein, ornithine decarboxylase, and S-adenosylmethionine decarboxylase proenzyme.
Experimental
Matched Description: … Putrescine is a solid. This compound belongs to the polyamines. ... Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine …
4'-Methylene-5,8,10-trideazaaminopterin
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is Methotrexate. It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
Investigational
Matched Description: … CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable …
Tesaglitazar
Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Investigational
Matched Description: … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves ... Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical …
PAC-113
PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates. PAC-113 is targeting oral...
Investigational
Matched Description: … It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found …
Orgotein
Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage. Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide radical into either the less damaging hydrogen peroxide or molecular oxygen. Hydrogen peroxide can be degraded by catalase. The antioxidant...
Investigational
Vet approved
Matched Description: … A notable exception is Lactobacillus plantarum. ... Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage …
Exarafenib
Investigational
Displaying drugs 11001 - 11025 of 11745 in total